المعرفة

هيدروكسي‌كارباميد

(تم التحويل من Hydroxycarbamide)

هيدروكسي‌كارباميد (إنگليزية: Hydroxycarbamide)، يُعرف أيضاً باسم هيدروكسي‌يوريا (إنگليزية: hydroxyurea)، هو دواء يستخدم لعلاج مرض الخلايا المنجلية، كثرة الصفيحات الأولية، ابيضاض الدم النقوي المزمن وسرطان عنق الرحم.[1][2] في مرض الخلايا المنجلية يزيد الهيموگلوبين الجنيني ويقلل عدد الهجمات.[1] يؤخذ هذا الدواء عن طريق الفم.[1]

هيدروكسي‌كارباميد
Structural formula
Hydroxyurea-3D-balls.png
البيانات السريرية
الأسماء التجاريةDroxia, Hydrea, Siklos, others
أسماء أخرىقالب:Infobox drug/localINNvariants
AHFS/Drugs.comMonograph
MedlinePlusa682004
License data
فئة السلامة
أثناء الحمل
  • AU: D
مسارات
الدواء		عن طريق الفم
رمز ATC
الحالة القانونية
الحالة القانونية
  • AU: S4 (Prescription only)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • EU: Rx-only
  • عموماً: ℞ (بوصفة فقط)
بيانات الحركية الدوائية
الأيضالكبد (إلى CO2 ويوريا)
Elimination half-life2–4 ساعة
الإخراجالكلى والرئتان
المعرفات
رقم CAS
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
CompTox Dashboard (EPA)
ECHA InfoCard100.004.384 Edit this at Wikidata
Chemical and physical data
التركيبCH4N2O2
الكتلة المولية76٫06 g·mol−1
3D model (JSmol)
Melting point133 to 136 °C (271 to 277 °F)
  (verify)

تشمل الآثار الجانبية الشائعة تثبيط نقي العظم، الحمى، فقدان الشهية، المشكلات النفسية، ضيق التنفس، والصداع.[1][2] وهناك أيضاً مخاوف من أنه يزيد خطر الإصابة بالسرطان لاحقاً.[1] استخدامه أثناء الحمل يضر بالجنين.[1] الهيدروكسي‌كارباميد أحد الأدوية المضادة للأورام. يُعتقد أنه يعمل عن طريق حصر تخليق الدنا.[1]

أُعتمد الهيدروكسي‌كارباميد للاستخدام الطبي في الولايات المتحدة عام 1967.[1] وهو ضمن قائمة الأدوية الأساسية لمنظمة الصحة العالمية.[3] الهيدروكسي‌كارباميد متوافر كدواء مكافئ.[1]

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

الاستخدامات الطبية

Hydroxycarbamide is used for the following indications:


الآثار الجانبية

Reported side effects are: neurological reactions (e.g., headache, dizziness, drowsiness, disorientation, hallucinations, and convulsions), nausea, vomiting, diarrhea, constipation, mucositis, anorexia, stomatitis, bone marrow toxicity (dose-limiting toxicity; may take 7–21 days to recover after the drug has been discontinued), megaloblastic anemia, thrombocytopenia, bleeding, hemorrhage, gastrointestinal ulceration and perforation, immunosuppression, leukopenia, alopecia (hair loss), skin rashes (e.g., maculopapular rash), erythema, pruritus, vesication or irritation of the skin and mucous membranes, pulmonary edema, abnormal liver enzymes, creatinine and blood urea nitrogen.[9]

Due to its negative effect on the bone marrow, regular monitoring of the full blood count is vital, as well as early response to possible infections. In addition, renal function, uric acid and electrolytes, as well as liver enzymes, are commonly checked.[10] Moreover, because of this, its use in people with leukopenia, thrombocytopenia or severe anemia is contraindicated.[11]

Hydroxycarbamide has been used primarily for the treatment of myeloproliferative diseases, which has an inherent risk of transforming to acute myeloid leukemia. There has been a longstanding concern that hydroxycarbamide itself carries a leukemia risk, but large studies have shown that the risk is either absent or very small. Nevertheless, it has been a barrier for its wider use in patients with sickle-cell disease.[12]

آلية العمل

Hydroxycarbamide decreases the production of deoxyribonucleotides[13] via inhibition of the enzyme ribonucleotide reductase by scavenging tyrosyl free radicals as they are involved in the reduction of nucleoside diphosphates (NDPs).[12]

In the treatment of sickle-cell disease, hydroxycarbamide increases the concentration of fetal hemoglobin. The precise mechanism of action is not yet clear, but it appears that hydroxycarbamide increases nitric oxide levels, causing soluble guanylyl cyclase activation with a resultant rise in cyclic GMP, and the activation of gamma globin gene expression and subsequent gamma chain synthesis necessary for fetal hemoglobin (HbF) production (which does not polymerize and deform red blood cells like the mutated HbS, responsible for sickle cell disease). Adult red cells containing more than 1% HbF are termed F cells. These cells are progeny of a small pool of immature committed erythroid precursors (BFU-e) that retain the ability to produce HbF. Hydroxyurea also suppresses the production of granulocytes in the bone marrow which has a mild immunosuppressive effect particularly at vascular sites where sickle cells have occluded blood flow.[12][14]

التواجد الطبيعي

Hydroxyurea has been reported as endogenous in human blood plasma at concentrations of approximately 30 to 200 ng/ml.[15]

الكيمياء

هيدروكسي‌كارباميد
المخاطر
خطر رئيسي Mutagen – Reproductive toxicity
ن.م.ع. مخطط تصويري  
ن.م.ع. كلمة الاشارة Danger
H340, H361
P201, P202, P281, P308+P313, P405, P501

Hydroxyurea has been prepared in many different ways since its initial synthesis in 1869.[16] Medical chemists, Dresler and Stein created Hydroxyurea from hydroxylamine, hydrochloric acid and potassium cyanide as a technical exercise in organic chemistry, as part of a series of experiments generating derivatives of urea. Hydroxyurea lay dormant for more than fifty years until it was studied as part of an investigation into the toxicity of protein metabolites.[17] Due to its chemical properties hydroxyurea was explored as an antisickling agent in the treatment of hematological conditions.

One common mechanism for synthesizing hydroxyurea is by the reaction of calcium cyanate with hydroxylamine nitrate in absolute ethanol and by the reaction of salt (i.e. sodium or potassium) cyanates and hydroxylamine hydrochloride in aqueous solution.[18] Hydroxyurea has also been prepared by converting a quaternary ammonium anion exchange resin from the chloride form to the cyanate form with sodium cyanate and reacting the resin in the cyanate form with hydroxylamine hydrochloride. This method of hydroxyurea synthesis was patented by Hussain et al. (2015).[19]

علم الأدوية

Hydroxyurea is a monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Similar to other antimetabolite anti-cancer drugs, it acts by disrupting the DNA replication process of dividing cancer cells in the body. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair.[20]

Biochemical research has explored its role as a DNA replication inhibitor[21] which causes deoxyribonucleotide depletion and results in DNA double strand breaks near replication forks (see DNA repair). Repair of DNA damaged by chemicals or irradiation is also inhibited by hydroxyurea, offering potential synergy between hydroxyurea and radiation or alkylating agents.[22]

Hydroxyurea has many pharmacological applications under the Medical Subject Headings classification system:[20]

  • Antineoplastic Agents – Substances that inhibit or prevent the proliferation of neoplasms.
  • Antisickling Agents – Agents used to prevent or reverse the pathological events leading to sickling of erythrocytes in sickle cell conditions.
  • Nucleic Acid Synthesis Inhibitors – Compounds that inhibit cell production of DNA or RNA.
  • Enzyme Inhibitors – Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction.
  • Cytochrome P-450 CYP2D6 Inhibitors – Acts as an inhibitor to one of the most important enzymes involved in the metabolism of xenobiotics in the body, CYP2D6 a member of the cytochrome P450 mixed oxidase system.

المجتمع والثقافة

الأسماء التجارية

Brand names include: Hydrea, Litalir, Droxia, and Siklos.[بحاجة لمصدر]

المصادر

  1. ^ أ ب ت ث ج ح خ د ذ "Hydroxyurea". The American Society of Health-System Pharmacists. Retrieved 8 December 2016.
  2. ^ أ ب "Hydrea 500 mg Hard Capsules – Summary of Product Characteristics (SPC) – (eMC)". www.medicines.org.uk. Archived from the original on 20 December 2016. Retrieved 14 December 2016.
  3. ^ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  4. ^ Harrison CN, Campbell PJ, Buck G, et al. (July 2005). "Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia". N. Engl. J. Med. 353 (1): 33–45. doi:10.1056/NEJMoa043800. PMID 16000354.
  5. ^ Lanzkron S, Strouse JJ, Wilson R, et al. (June 2008). "Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease". Ann. Intern. Med. 148 (12): 939–55. doi:10.7326/0003-4819-148-12-200806170-00221. PMC 3256736. PMID 18458272.
  6. ^ Sharma VK, Dutta B, Ramam M (2004). "Hydroxyurea as an alternative therapy for psoriasis". Indian J Dermatol Venereol Leprol. 70 (1): 13–7. PMID 17642550. Archived from the original on 2009-07-03.
  7. ^ Escribano, L.; Álvarez-Twose, I. N.; Sánchez-Muñoz, L.; Garcia-Montero, A.; Núñez, R.; Almeida, J.; Jara-Acevedo, M.; Teodósio, C.; et al. (2009). "Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients". Journal of Allergy and Clinical Immunology. 124 (3): 514–521. doi:10.1016/j.jaci.2009.05.003. PMID 19541349.
  8. ^ Dalziel, K.; Round, A.; Stein, K.; Garside, R.; Price, A. (2004). "Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: A systematic review and economic analysis". Health Technology Assessment. 8 (28): iii, ii1–120. doi:10.3310/hta8280. PMID 15245690.
  9. ^ Liebelt, E.; Balk, S.; Faber, W.; Fisher, J.; Hughes, C.; Lanzkron, S.; Lewis, K.; Marchetti, F.; Mehendale, H.; Rogers, J. M.; Shad, A. T.; Skalko, R. G.; Stanek, E. J. (2007). "NTP-CERHR expert panel report on the reproductive and developmental toxicity of hydroxyurea". Birth Defects Research, Part B. 80 (4): 259–366. doi:10.1002/bdrb.20123. PMID 17712860.
  10. ^ Longe, Jacqueline L. (2002). Gale Encyclopedia Of Cancer: A Guide To Cancer And Its Treatments. Detroit: Thomson Gale. pp. 514–516. ISBN 978-1-4144-0362-5.
  11. ^ "HYDREA" (PDF). Accessdata.fda.gov. US Food and Drug Administration.
  12. ^ أ ب ت Platt OS (2008). "Hydroxyurea for the treatment of sickle cell anemia". N. Engl. J. Med. 358 (13): 1362–9. doi:10.1056/NEJMct0708272. PMID 18367739.
  13. ^ "hydroxyurea" في قاموس دورلاند الطبي
  14. ^ Cokic VP, Smith RD, Beleslin-Cokic BB, et al. (2003). "Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase". J Clin Invest. 111 (2): 231–9. doi:10.1172/JCI16672. PMC 151872. PMID 12531879.
  15. ^ Kettani, T; Gulbis, B; Ferster, A; Kumps, A (2009). "Plasma hydroxyurea determined by gas chromatography-mass spectrometry". Journal of Chromatography B. 877 (4): 446–450. doi:10.1016/j.jchromb.2008.12.048. PMID 19144580.
  16. ^ Dresler WFC; Stein R (1869). "Ueber den Hydroxylharnstoff". Justus Liebigs Ann. Chem. 150 (2): 1317–22. doi:10.1002/jlac.18691500212.
  17. ^ Rees C. David (2011). "The rationale for using hydroxycarbamide in the treatment of sickle cell disease". Haematologica. 96 (4): 488–491. doi:10.3324/haematol.2011.041988. PMC 3069221. PMID 21454878.
  18. ^ Graham P.J. (1955). "Synthesis of Ureas". US Patent No. 2, 705, 727. E.I. du Pont de Nemours & Co., Wilmington, DE. {{cite journal}}: Cite journal requires |journal= (help)
  19. ^ Hussain KA, Abid DS, Adam GA (2016). "New Method for Synthesis of Hydroxyurea and Some of its Polymer Supported Derivatives As New Controlled Release Drugs". Journal of Basrah Research. 41 (1). doi:10.13140/RG.2.1.3607.2720.
  20. ^ أ ب "Pharmacology and Biochemistry". PubChem. Archived from the original on 2017-05-18.
  21. ^ Koç A, Wheeler LJ, Mathews CK, Merrill GF (January 2004). "Hydroxyurea arrests DNA replication by a mechanism that preserves basal dNTP pools". J. Biol. Chem. 279 (1): 223–30. doi:10.1074/jbc.M303952200. PMID 14573610. S2CID 2675195.[dead link]
  22. ^ Yarbro JW (1992). "Mechanism of Action". Seminars in Oncology. 19 (3): 1–10. PMID 1641648.

وصلات خارجية

  • "Hydroxyurea". Drug Information Portal. U.S. National Library of Medicine.
تمّ الاسترجاع من "https://www.marefa.org/w/index.php?title=هيدروكسي‌كارباميد&oldid=2501894"